Physician profile
Qing Li
NPI 1376823484
$2,154.70
in general payments reported to CMS, 2019-2025
12 companies · $879 in 2025
The $879 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $42.26 · 2023: $437 · 2024: $602 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,917.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $485.10 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $458.18 | 2023-2025 | |
| Abbvie INC. | $401.20 | 2021-2025 | |
| Pfizer INC. | $238.65 | 2024-2025 | |
| Janssen Biotech, INC. | $170.95 | 2021-2025 | Tremfya |
| Amgen INC. | $124.07 | 2021-2025 | Enbrel, Enbrel, Otezla |
| Radius Health, INC. | $98.16 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $79.34 | 2023-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $32.13 | 2023 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $24.13 | 2024 | |
| Abbott Laboratories | $22.13 | 2024 | Cardiomems |
| Sandoz INC. | $20.66 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qing Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.